Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.
Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body’s immune system to inflict damage oncancer cells in the body and has shown promise in treating a broad spectrum of cancers.
Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).
Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), announces that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the …
Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides this shareholder update as a summary of R&D progress in 2020 and a guide to what 2021 is expected to hol…